Description
Key facts
Detection method:Fluorescent,
Sample types:Inhibitor compounds,
Assay Platform:Microplate (12 x 8 well strips)
Product details:
Monoacylglycerol Lipase/MGL Inhibitor Screening Kit provides a straightforward method to identify inhibitors of human MGL. In the assay, human recombinant MGL is used to cleave an MGL substrate, resulting in a fluorescence increase that is abrogated by the presence of an inhibitor for this enzyme. Specific inhibitors for this enzyme are of great clinical interest due to the central role for MGL in lipid metabolism and energy storage.
Simple one-step reaction. Takes only 1-2 hours.
This product is manufactured by BioVision, an Abcam company and was previously called K474 Monoacylglycerol Lipase Inhibitor Screening Kit (Fluorometric). K474-100 is the same size as the 100 test size of ab283388.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Monoacylglycerol lipase (MGL) also known as MAGL or lipase 63 is an enzyme with a mass of approximately 33 kDa. MGL primarily functions in lipid metabolism by hydrolyzing 2-monoacylglycerol (2-MAG) into free fatty acids and glycerol. This enzyme is expressed in many tissues with high expression in the brain liver and adipose tissue. Its activity plays a significant role in the breakdown of monoacylglycerol an important intermediate in the endocannabinoid signaling system.
Biological function summary
MGL contributes to the regulation of energy homeostasis by controlling the levels of 2-monoacylglycerol. It catalyzes the final step in the degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG) which is important for modulating inflammation pain and mood. MGL is not known to be part of a larger protein complex. In the brain its action helps terminate endocannabinoid signaling therefore influencing neurotransmission and synaptic plasticity.
Pathways
MGL plays a critical role in the endocannabinoid and glycerolipid metabolism pathways. In the endocannabinoid system it interacts with the cannabinoid receptors CB1 and CB2 by regulating 2-AG levels. The protein's role in glycerolipid metabolism involves its interaction with long-chain acyl-CoA synthetase and fatty acid oxidation pathways which are essential for maintaining lipid balance and cellular energy.
MGL has been linked to neurodegenerative diseases and cancer. In neurodegenerative diseases like Alzheimer’s dysregulation of MGL activity may lead to altered endocannabinoid signaling impacting neuronal health. In cancer increased MGL activity can promote tumor progression by providing cancer cells with fatty acids for growth and survival. MGL's interaction with proteins such as fatty acid synthase highlights its importance in cancer metabolism.
